To evaluate the sufficiency of loss of MOXD1 to drive neuroblastomas, we knocked out MOXD1 with CRISPR-Cas9 in the MES-dominant SH-EP cells that express high endogenous levels of MOXD1 (Fig. 2E). Here, MOXD1 is linked to neuroblastoma.